Triple-Agonist weist neuen Weg bei Diabetes
Nutrients | Free Full-Text | Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone Peptide-Derived G Protein Coupled Receptor Agonists
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept - ScienceDirect
Are peptide conjugates the golden therapy against obesity?
Alzheimer's: 'Triple-action' diabetes drug shows promise as treatment
Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy | SpringerLink
Frontiers | GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Neuroprotective effects of HM15211, a novel long-acting GLP-1/GIP/glucagon triple agonist in the neurodegenerative disease models - Media Centre | EASD
GLP-1 Archives - Immune System Research
Ly3437943 (LY), a novel triple GIP/GLP-1/glucagon receptor agonist, provides glucose lowering and weight loss in patients with type 2 diabetes after 12 weeks of treatment | Medfyle
Neuroprotective effects of HM15211, a novel long-acting GLP-1/GIP/glucagon triple agonist in the neurodegenerative disease models - Media Centre | EASD
Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations | Journal of Medicinal Chemistry
Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis | Journal of Medicinal Chemistry
Effects, working principles and target tissues of dual agonists... | Download Scientific Diagram
IJMS | Free Full-Text | The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome
Potent body weight loss, and therapeutic efficacy in a NASH animal model by a novel long-acting GLP-1/Glucagon/GIP tri-agonist (HM15211) - Media Centre | EASD
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial - The Lancet
The novel GIP, GLP-1, and Glucagon Triple Receptor Agonist LY3437943 Exhibits Robust Efficacy in Preclinical Models of Obesity a
Frontiers | Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
Innovative Behandlungsmethoden - Duale und Triple-Agonisten – die Zukunft der Typ-2-Diabetestherapie?
Clinical Focus on GLP-1 Agonists in Type 2 Diabetes Mellitus
